Product Pipeline
EyePoint has developed five FDA-approved products utilizing our proprietary DurasertTM and VerisomeTM Technologies.
We are utilizing our Durasert bioerodible technology platform in collaboration with other pharmaceutical companies to develop new sustained-release products to treat retinal diseases and other ocular conditions, and are available to collaborate on our VerisomeTM Technology.
| Product/Program | Phase |
|---|---|
| Dexycu (dexamethasone intraocular suspension) 9% | Approved |
| Yutiq (fluocinolone acetonide intravitreal implant) 0.18 mg | Approved |
| Yutiq shorter duration treatment | Preclinical |
| Durasert TKI Potential Indication: Wet AMD | Preclinical |
| Collaboration on glaucoma | Preclinical |
| Verisome Technology - PGE Potential Indication: glaucoma | Preclinical |
| Verisome Technology - NSAID Potential Indication: cataract surgery inflammation | Preclinical |
Please complete the form below to receive information on the availability of Dexycu.
Please complete the form below to receive information on the availability of Yutiq.
YutiqTM Shorter Duration for Posterior Uveitis
Potential Indication: posterior segment uveitis
EyePoint is currently developing a shorter-duration sustained-release fluocinolone acetonide product in the proven DurasertTM Technology.
DurasertTM Bioerodible TKI
Potential Indication: Wet AMD
EyePoint is focused on developing a sustained-release bioerodible device containing a tyrosine kinase inhibitor (TKI) to assess its potential to treat wet AMD. In-vitro release profiles have been assessed for several TKIs.